We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 589

Takeda acquires access to Envoy’s CNS drug pipeline and bacTRAP technology

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 15 2012

Takeda America Holdings, Inc. has reportedly acquired Envoy Therapeutics, Inc. in a deal worth $140 million, including an up-front payment and progressdependent milestone payments

FDA warns competing drug makers over unsubstantiated superiority claims

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 15 2012

The U.S. Food and Drug Administration has sent warning letters to competing drug manufacturers for allegedly promoting their neonatal respiratory distress syndrome treatments using “unsubstantiated superiority claims” that also “omit and minimize important risk information, and present unsubstantiated claims for the drug product”

New infringement lawsuit filed to protect BRCA1 and BRCA2 patents

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 26 2014

Myriad Genetics has brought a new infringement lawsuit against a company offering a next-generation sequencing test that analyzes the BRCA1 and BRCA2

Massachusetts issues painkiller restrictions as ban expires

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 1 2014

The Massachusetts Department of Public Health has issued an order that places restrictions on those prescribing hydrocodone-only medications; the

Physicians urge FDA to allow distinctive names for biosimilars

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 21 2014

A coalition of organizations representing specialist physicians and individual physicians have authored a letter to U.S. Food and Drug Administration

Biotech secures $5.3 million for immunosuppressant drug research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

San Francisco-based startup, Nurix, Inc., which reportedly develops T-cellspecific immunosuppressants used to treat autoimmune diseases such as

Federal Circuit says certain human genes may be patented

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 4 2011

In a ruling likely to be appealed to the U.S. Supreme Court, a divided Federal Circuit Court of Appeals panel has determined that genetic discoveries may, to a certain extent, be patented

Diabetes and obesity biotech secures $50 million in Series C financing round

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 1 2013

According to a news source, NGM Biopharmaceuticals, Inc. has completed a $50-million Series C financing round that included new investors from the

Myriad Genetics brings new BRCA1BRCA2 infringement suits

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • December 12 2013

Myriad Genetics now reportedly has six pending infringement lawsuits involving its BRCA1 and BRCA2 patents, with Invitae Corp. and Laboratory Corp

Advocacy coalition agrees to drop nanotechnology lawsuit against FDA

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 7 2012

A coalition of advocacy organizations has reportedly agreed to dismiss as moot its lawsuit seeking an order requiring the Food and Drug Administration (FDA) to respond to its 2006 petition asking the agency to regulate products containing nanomaterials